Nippon Life Global Investors Americas’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.67M | Buy |
+51,670
| New | +$4.33M | 0.19% | 62 |
|
|
2025
Q4 | – | Sell |
-51,840
| Closed | -$4.03M | – | 109 |
|
|
2025
Q3 | $4.03M | Sell |
51,840
-9,460
| -15% | -$739K | 0.17% | 66 |
|
|
2025
Q2 | $4.79M | Sell |
61,300
-8,150
| -12% | -$608K | 0.21% | 67 |
|
|
2025
Q1 | $5.03M | Hold |
69,450
| – | – | 0.25% | 67 |
|
|
2024
Q4 | $5.14M | Buy |
69,450
+4,570
| +7% | +$320K | 0.24% | 71 |
|
|
2024
Q3 | $4.28M | Buy |
+64,880
| New | +$4.71M | 0.18% | 74 |
|
|
2024
Q1 | – | Sell |
-21,190
| Closed | -$1.62M | – | 118 |
|
|
2023
Q4 | $1.62M | Sell |
21,190
-6,990
| -25% | -$486K | 0.09% | 95 |
|
|
2023
Q3 | $1.95M | Sell |
28,180
-34,020
| -55% | -$2.73M | 0.12% | 89 |
|
|
2023
Q2 | $5.87M | Sell |
62,200
-49,550
| -44% | -$4.31M | 0.4% | 57 |
|
|
2023
Q1 | $9.25M | Buy |
+111,750
| New | +$8.78M | 0.59% | 50 |
|
|
2022
Q4 | – | Sell |
-19,250
| Closed | -$1.59M | – | 132 |
|
|
2022
Q3 | $1.59M | Sell |
19,250
-37,680
| -66% | -$3.63M | 0.11% | 89 |
|
|
2022
Q2 | $5.41M | Sell |
56,930
-10,190
| -15% | -$1.05M | 0.35% | 83 |
|
|
2022
Q1 | $7.9M | Buy |
67,120
+6,320
| +10% | +$709K | 0.42% | 65 |
|
|
2021
Q4 | $7.88M | Hold |
60,800
| – | – | 0.37% | 74 |
|
|
2021
Q3 | $6.88M | Sell |
60,800
-4,580
| -7% | -$523K | 0.36% | 78 |
|
|
2021
Q2 | $6.77M | Buy |
65,380
+11,950
| +22% | +$1.13M | 0.34% | 83 |
|
|
2021
Q1 | $4.47M | Hold |
53,430
| – | – | 0.24% | 104 |
|
|
2020
Q4 | $4.88M | Hold |
53,430
| – | – | 0.29% | 88 |
|
|
2020
Q3 | $4.26M | Hold |
53,430
| – | – | 0.28% | 84 |
|
|
2020
Q2 | $3.69M | Buy |
+53,430
| New | +$3.8M | 0.26% | 92 |
|
|
2019
Q3 | – | Sell |
-47,070
| Closed | -$2.9M | – | 142 |
|
|
2019
Q2 | $2.9M | Buy |
47,070
+14,430
| +44% | +$873K | 0.22% | 106 |
|
|
2019
Q1 | $2.08M | Sell |
32,640
-216,840
| -87% | -$12.4M | 0.17% | 124 |
|
|
2018
Q4 | $12.7M | Sell |
249,480
-45,690
| -15% | -$2.31M | 1.1% | 30 |
|
|
2018
Q3 | $17.1M | Buy |
295,170
+30,540
| +12% | +$1.49M | 1.31% | 23 |
|
|
2018
Q2 | $12.8M | Sell |
264,630
-58,920
| -18% | -$2.75M | 1.02% | 34 |
|
|
2018
Q1 | $15M | Buy |
323,550
+14,310
| +5% | +$621K | 1.24% | 21 |
|
|
2017
Q4 | $11.6M | Hold |
309,240
| – | – | 0.93% | 37 |
|
|
2017
Q3 | $11.3M | Sell |
309,240
-30,510
| -9% | -$1.16M | 0.96% | 37 |
|
|
2017
Q2 | $13.4M | Buy |
339,750
+139,770
| +70% | +$5.1M | 1.15% | 29 |
|
|
2017
Q1 | $6.27M | Buy |
199,980
+28,950
| +17% | +$906K | 0.56% | 64 |
|
|
2016
Q4 | $5.34M | Buy |
+171,030
| New | +$5.54M | 0.49% | 76 |
|
Other funds holding EW
Nippon Life Global Investors Americas's EW Position: Q2 2026 in Review
Nippon Life Global Investors Americas opened a new position in Edwards Lifesciences (EW) in Q2 2026: 51,670 shares worth $4.67M. The stake represents 0.19% of the portfolio and ranks #62 among its holdings. This is a return to the name: Nippon Life Global Investors Americas previously reported a position in EW as recently as Q3 2025.
Nippon Life Global Investors Americas first reported a position in EW in Q4 2016 and has held it in 31 quarters since. The position peaked at $17.1M in Q3 2018. 1,337 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Nippon Life Global Investors Americas held 51,670 shares of Edwards Lifesciences worth $4.67M as of Q2 2026.
- Edwards Lifesciences was a new Nippon Life Global Investors Americas position in Q2 2026.
- Edwards Lifesciences made up 0.19% of Nippon Life Global Investors Americas's portfolio in Q2 2026, its #62 holding.
- Nippon Life Global Investors Americas first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 31 quarters since.
- Nippon Life Global Investors Americas's Edwards Lifesciences position peaked at $17.1M in Q3 2018.
- 1,337 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Nippon Life Global Investors Americas's 13F filing for Q2 2026, filed 6 Aug 2026.